# Revlimid in Transfusion Dependent Patients

> **NCT01178814** · PHASE2 · COMPLETED · sponsor: **Columbia University** · enrollment: 57 (actual)

## Conditions studied

- Myelodysplastic Syndrome

## Interventions

- **DRUG:** Revlimid (Lenalidomide)

## Key facts

- **NCT ID:** NCT01178814
- **Lead sponsor:** Columbia University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06-01
- **Primary completion:** 2022-09-01
- **Final completion:** 2022-12-07
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2024-06-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01178814

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01178814, "Revlimid in Transfusion Dependent Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01178814. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*